Drug intelligence / Profile preview

LYB027

Development stage: Phase 1
Lead developer: Patronus Biotech
Modality: Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

LYB027 is an investigational recombinant malaria vaccine candidate developed by Guangzhou Patronus Biotech. It is designed to prevent malaria caused by Plasmodium falciparum. The vaccine is formulated with Patronus Biotech's proprietary A02B adjuvant, which contains QS-21 and monophosphoryl lipid A (MPL) to enhance both humoral and cellular immune responses. LYB027 is currently being evaluated in a Phase I clinical trial in healthy adults to assess its safety, tolerability, and immunogenicity.

Beyond the preview

Go deeper on LYB027.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYB027.